Изображение на обложке

Применение «омиксных» технологий для антидопингового контроля последних лет

P. V. Postnikov, V. I. Pavlov, L. E. Romanovskaya, Yu. A. Efimova, Z. G. Ordzhonikidze

Аннотация


Масштабный кризис в международном спорте, вызванный распространением коронавируса, привел к отмене многих крупных соревнований и лишил спортсменов доступа к тренировочным объектам. Это привело к ухудшению физической подготовки спортсменов, что способствовало увеличению возможности приема запрещенных веществ и методов для поддержания формы. Достижения науки последних лет в области «омиксных» технологий создают потенциальные риски их применения для улучшения спортивных результатов. Стали актуальными исследования по разработке новых аналитических методик идентификации допинга на основе последних достижений в области транскриптомики, протеомики, геномики и метаболомики. В обзоре обобщены и проанализированы новые подходы по обнаружению запрещенных в спорте веществ и методов на основе «омиксных» технологий.  Результаты проведенных исследований могут быть использованы для повышения качества и эффективности современного допинг-контроля.

Ключевые слова: антидопинговый контроль; «омиксные» технологии; геномика; транстриптомика; протеомика; метаболомика

Полный текст:

PDF

Литература


REFERENCES

Di Trana A., Carlier J., Berretta P., Zaami S., Ricci G. Consequences of COVID-19 Lockdown on the Misuse and Marketing of Addictive Substances and New Psychoactive Substances. Frontiers in Psychiatry, 2020, vol. 11, article 584462. doi: 10.3389/fpsyt.2020.584462.

Javed N., Zuber M., Amin S., Bugis B., Al-Mohaithef M. COVID-19 cases and deaths after implementation of prevention strategies. Eastern Mediterranean Health J., 2022, vol. 28, no. 2, pp. 95-107. doi: 10.26719/emhj.21.067.

Negro F., Di Trana A., Marinelli S. The effects of the COVID-19 pandemic on the use of the performance-enhancing drugs. Acta Biomed, 2022, vol. 92, no. 6, article 2021401. doi: 10.23750/abm.v92i6.12377.

Pitsiladis Y., Muniz-Pardos B., Miller M., Verroken M. Sport Integrity Opportunities in the Time of Coronavirus. Sports Med., 2020, vol. 50, no. 10, pp. 1701-1702. doi: 10.1007/s40279-020-01316-6.

Ginevičienė V., Utkus A., Pranckevičienė E., Semenova E. A., Hall E. C. R., Ahmetov I. I. Perspectives in Sports Genomics. Biomedicines, 2022, vol. 10, no. 2, article 298. doi: 10.3390/biomedicines10020298.

Muniz-Santos R., Watt P., Jurisica I., Cameron L. C. Metabolic response: nexus or nemesis for the understanding of sports nutrition and doping. Front. Nutr., 2023, vol. 10, article 1306052. doi: 10.3389/fnut.2023.1306052.

Elrayess M. A., Botrè F., Palermo A. OMICS-Based Approaches in Sports Research. Front Mol. Biosci., 2022, vol. 9, article 870728. doi: 10.3389/fmolb.2022.870728.

Lima G., Muniz-Pardos B., Kolliari-Turner A., Hamilton B., Guppy F.M., Grivas G., Bosch A., Borrione P., Di Gianfrancesco A., Fossati C., Pigozzi F., Pitsiladis Y. Anti-doping and other sport integrity challenges during the COVID-19 pandemic. J. sports medicine and physical fitness, 2021, vol. 61, no. 8, pp. 1173-1183. doi: 10.23736/S0022-4707.21.12777-X.

Muniz-Santos R., Magno-França A., Jurisica I., Cameron L. C. From Microcosm to Macrocosm: The-Omics, Multiomics, and Sportomics Approaches in Exercise and Sports. OMICS, 2023, vol. 27, no. 11, pp. 499-518. doi: 10.1089/omi.2023.0169.

Aborode A.T., Awuah W.A., Mikhailova T., Abdul-Rahman T., Pavlock S., Kundu M., Yarlagadda R., Pustake M., da Silva Correia I.F., Mehmood Q., Shah P., Mehta A., Ahmad S., Asekun A., Nansubuga E.P., Amaka S.O., Shkodina A., Alexiou A. OMICs Technologies for Natural Compounds-based Drug Development. Current Topics Medicinal Chem., 2022, vol. 22, no. 21, pp. 1751-1765. doi: 10.2174/1568026622666220726092034.

Wang G., Durussel J., Shurlock J., Mooses M., Fuku N., Bruinvels G., Pedlar C., Burden R., Murray A., Yee B., Keenan A., McClure J. D., Sottas P.-E., Pitsiladis Y. P. Validation of whole-blood transcriptome signature during microdose recombinant human erythropoietin (rHuEpo) administration. BMC Genomics, 2017, vol. 18, no. 8, article 817. doi: 10.1186/s12864-017-4191-7.

Durussel J., Haile D.W., Mooses K., Daskalaki E., Beattie W., Mooses M., Mekonen W., Ongaro N., Anjila E., Patel R.K., Padmanabhan N., McBride M.W., McClure J.D., Pitsiladis Y.P. Blood transcriptional signature of recombinant human erythropoietin administration and implications for antidoping strategies. Physiological Genomics, 2016, vol. 48, pp. 202-209. doi: 10.1152/physiolgenomics.00108.2015.

WADA Technical document TD2021DBS [World Anti-doping Agency]: Available at: https://www.wada-ama.org/sites/default/files/item_6_3_3_attach_1_finalversion_td2021dbs_fina.pdf (accessed 17 April 2025).

Reverter-Branchat G., Ventura R., Ezzel Din M., Mateus J., Pedro C., Segura J. Detection of erythropoiesis-stimulating agents in a single dried blood spot. Drug Test. Anal., 2018, vol. 10, pp. 1496-1507. doi: 10.1002/dta.2418.

Salamin O., Gottardo E., Schobinger C., Reverter-Branchat G., Segura J., Saugy M., Kuuranne T., Tissot J.-D., Favrat B., Leuenberger N. Detection of stimulated erythropoiesis by the RNA-based 5′-aminolevulinate synthase 2 biomarker in dried blood spot samples. Clinical Chem., 2019, vol. 65, pp. 1563-1571. doi: 10.1373/clinchem.2019.306829.

Loria F., Manfredi M., Reverter-Branchat G., Segura J., Kuuranne T., Leuenberger N. Automation of RNA-based biomarker extraction from dried blood spots for the detection of blood doping. Bioanalysis, 2020, vol. 12, pp. 729-736. doi: 10.4155/bio-2020-0041.

Loria F., Maret E., Schobinger C., Kuuranne T., Grabherr S., Leuenberger N. The effects of iron injection on blood doping biomarkers in dried blood spots. Drug Test. Anal., 2023, vol. 15, no. 4, pp. 444-448. doi: 10.1002/dta.3407.

Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., Galas D.J., Wang K. The microRNA spectrum in 12 body fluids. Clinical Chem., 2010, vol. 56, no. 11, pp. 1733-1741. doi: 10.1373/clinchem.2010.147405.

Loria F., Grabherr S., Kuuranne T., Leuenberger N. Use of RNA biomarkers in the antidoping field. Bioanalysis, 2024, vol. 16, no. 10, pp. 475-484. doi: 10.4155/bio-2023-0251.

Postnikov P.V., Radus F.V., Efimova Yu.A., Pronina I.V. Determination of possible microRNA-markers of cobalt abuse by real-time qPCR using hypoxia signaling pathway panels. Fine Chem. Tech., 2023, vol. 18, no. 1, pp. 65-74. doi: 10.32362/2410-6593-2023-18-1-65-74

Leuenberger N., Saugy M. Circulating microRNAs: the future of biomarkers in antidoping field. Advances in Experimental Medicine and Biology, 2015, vol. 888, pp. 401-408. doi: 10.1007/978-3-319-22671-2_20.

Lehtihet M., Bhuiyan H., Dalby A., Ericsson M., Ekström L. Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting two weeks' administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers. Drug Test. Anal., 2019, vol. 11, no. 3, pp. 411-421. doi: 10.1002/dta.2506.

Kelly B.N., Haverstick D.M., Lee J.K., Thorner M.O., Vance M.L., Xin W., Bruns D.E. Circulating microRNA as a biomarker of human growth hormone administration to patients. Drug Test. Anal., 2014, vol. 6, no. 3, pp. 234-238. doi: 10.1002/dta.1469.

Sessa F., Salerno M., Di Mizio G., Bertozzi G., Messina G., Tomaiuolo B., Pisanelli D., Maglietta F., Ricci P., Pomara C. Anabolic Androgenic Steroids: Searching New Molecular Biomarkers. Frontiers in Pharmacology, 2018, vol. 9, article 1321. doi: 10.3389/fphar.2018.01321.

Postnikov P.V., Ordzhonikidze Z.G., Khanferyan R.A., Efimova Yu.A., Pronina I.V. MiR-378a-3p and miR-491-5p as markers of xenon abuse in doping control. Sports medicine: research and practice, 2023, vol. 13, no. 4, pp. 54-64. doi: 10.47529/2223-2524.2023.4.8.

Mussack V., Wittmann G., Pfaffl M.W. On the trail of blood doping-microRNA fingerprints to monitor autologous blood transfusions in vivo. American J. Hematology, 2021, vol. 96, no. 3, pp. 338-353. doi: 10.1002/ajh.26078.

Hassanpour M., Salybekov A.A. Whispers in the Blood: Leveraging MicroRNAs for Unveiling Autologous Blood Doping in Athletes. Int. J. Mol. Sci., 2023, vol. 25, no. 1, article 249. doi: 10.3390/ijms25010249.

Sugasawa T., Kanki Y., Komine R., Watanabe K., Takekoshi K. Identification of RNA Markers in Red Blood Cells for Doping Control in Autologous Blood Transfusion. Genes (Basel), 2022, vol. 13, no. 7, article 1255. doi: 10.3390/genes13071255.

Bouchard C., Rankinen T., Timmons J.A. Genomics and Genetics in the Biology of Adaptation to Exercise. Compr. Physiol., 2011, vol. 1, no. 3, pp. 1603-1648. doi: 10.1002/cphy.c100059.

Gineviciene V., Jakaitiene A., Aksenov M.O., Aksenova A.V., Astratenkova A.D., Egorova E.S., Gabdrakhmanova L.J., Tubelis L., Kucinskas V., Utkus A. Association analysis of ACE, ACTN3 and PPARGC1A gene polymorphisms in two cohorts of European strength and power athletes. Biol. Sport., 2016, vol. 33, article 199. doi: 10.5604/20831862.1201051.

Tozaki T., Hamilton N. Control of gene doping in human and horse sports. Gene Therapy, 2022, vol. 29, no. 3-4, pp. 107-112. doi: 10.1038/s41434-021-00267-5.

Paßreiter A., Thomas A., Grogna N., Delahaut P., Thevis M. First steps toward uncovering gene doping with CRISPR/Cas by identifying SpCas9 in plasma via HPLC−HRMS/MS. Anal. Chem., 2020, vol. 92, pp. 16322-16328. doi: 10.1021/acs.analchem.0c04445.

Paßreiter A., Naumann N., Thomas A., Grogna N., Delahaut P., Thevis M. Detection of sgRNA via SHERLOCK as Potential CRISPR Related Gene Doping Control Strategy. Anal Chem., 2024, vol. 96, no. 19, pp. 7452-7459. doi: 10.1021/acs.analchem.3c05776.

Zhou X., He S., Zezhou L., Jiayu W., Zhou W., Liu X., Zhao M., Zhang L. Discovery of c.577del in EPO: Investigations into endogenous EPO double-band detected in blood with SAR-PAGE. Drug Test. Anal., 2022, vol. 14, no. 4, pp. 622-633. doi: 10.1002/dta.3200.

WADA Technical document TD2024EPO [World Anti-Doping Agency] Available at: https://www.wada-ama.org/sites/default/files/2024-03/td2024epo_eng_final.pdf (accessed 20 March 2025).

Sugasawa T., Hirokawa A., Otani N., Kanki Y., Nguyen K.D., Takemasa T., Watanabe K., Takeuchi Y., Yahagi N., Takahashi Y. Detection Method for Gene Doping in a Mouse Model Expressing Human Erythropoietin from Adeno-Associated Virus Vector-9. Genes (Basel), 2024, vol. 15, no. 6, article 709. doi: 10.3390/genes15060709.

Semenova E. A., Miyamoto-Mikami E., Akimov E. B., Al-Khelaifi F., Murakami H., Zempo H., Kostryukova E. S., Kulemin N.A., Larin A.K., Borisov O.V., Miyachi M., Popov D.V., Boulygina E.A., Takaragawa M., Kumagai H., Naito H., Pushkarev V.P., Dyatlov D.A., Lekontsev E.V., Pushkareva Yu.E., Andryushchenko L. B., Elrayess M.A., Generozov E.V., Fuku N., Ahmetov I.I. The association of HFE gene H63D polymorphism with endurance athlete status and aerobic capacity: novel findings and a meta-analysis. Eur. J. Appl. Physiol., 2020, vol. 120, no. 3, pp. 665-673. doi: 10.1007/s00421-020-04306-8.

Mesonzhnik N. V., Postnikov P. V., Appolonova S. A., Krotov G. I. Characterization and Detection of Erythropoietin Fc Fusion Proteins Using Liquid Chromatography-Mass Spectrometry, 2018, J. Proteome Res., vol. 17, no. 1, pp. 689-697. doi: 10.1021/acs.jproteome.7b00739.

Walpurgis K., Thomas A., Lange T., Reichel C., Geyer H., Thevis M. Combined detection of the ActRII-Fc fusion proteins Sotatercept (ActRIIA-Fc) and Luspatercept (modified ActRIIB-Fc) in serum by means of immunoaffinity purification, tryptic digestion, and LC-MS/MS. Drug Test Anal., 2018, vol. 10, no. 11-12, pp. 1714-1721. doi: 10.1002/dta.2513.

Lima G., Shurlock J., Wang G., Karanikolou A., Sutehall S., Pitsiladis Y. P., D'Alessandro A. Metabolomic Profiling of Recombinant Erythropoietin (rHuEpo) in Trained Caucasian Athletes. Clin. J. Sport Med., 2023, vol. 33, no. 5, pp. 123-134. doi: 10.1097/JSM.0000000000001074.

Narduzzi L., Buisson C., Morvan M.-L., Marchand A., Audran M., Bouc Y. Le, Varlet-Marie E., Ericsson M., Le Bizec B., Dervilly G. Coupling Complete Blood Count and Steroidomics to Track Low Doses Administration of Recombinant Growth Hormone: An Anti-Doping Perspective. Front. Mol. Biosci., 2021, vol. 8, article 683675. doi: 10.3389/fmolb.2021.683675.

Krumm B., Saugy J.J., Botrè F., Donati F., Faiss R. Indirect biomarkers of blood doping: A systematic review. Drug Test. Anal., 2024, vol. 16, no. 1, pp. 49-64. doi: 10.1002/dta.3514.

Athlete Biological Passport (ABP) Operating Guidelines [World Anti-doping Agency] Available at: https://www.wada-ama.org/en/resources/world-anti-doping-program/athlete-biological-passport-abp-operating-guidelines (accessed 20 May 2025).

Robach P., Gammella E., Recalcati S., Girelli D., Castagna A., Roustit M., Lundby C., Lundby A.-K., Bouzat P., Vergès S., Séchaud G., Banco P., Uhr M., Cornu C., Sallet P., Cairo G. Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure. Haematologica, 2021, vol. 106, no. 2, pp. 384-390. doi: 10.3324/haematol.2019.233874.

Andersen A.B., Bejder J., Bonne T.C., Sørensen H., Sørensen H., Jung G., Ganz T., Nemeth E., Secher N.H., Johansson P.I., Nordsborg N.B. Hepcidin and Erythroferrone Complement the Athlete Biological Passport in the Detection of Autologous Blood Transfusion. Med. Sci. Sports Exerc., 2022, vol. 54, no. 9, pp. 1604-1616. doi: 10.1249/MSS.0000000000002950.

Andersen A.B., Bonne T.C., Bejder J., Jung G., Ganz T., Nemeth E., Olsen N.V., Huertas J.R., Nordsborg N.B. Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2021, vol. 321, no. 2, pp. 152-161. doi: 10.1152/ajpregu.00070.2021.

Thevis M., Kuuranne T., Geyer H. Annual banned-substance review: analytical approaches in human sports drug testing 2019/2020. Drug Test. Anal., 2021, vol. 13, pp. 8-35. doi: 10.1002/dta.2969.

Turner A.K., Lima G., Hamilton B., Pitsiladis Y. Analysis of Anti - Doping Rule Violations That Have Impacted Medal Results at the Summer Olympic Games 1968 – 2012. Sports medicine, 2021, vol. 9, pp. 1-9. doi: 10.1007/s40279-021-01463-4.

Pitsiladis Y., Ferriani I., Geistlinger M., de Hon O., Bosch A., Pigozzi F. A Holistic Antidoping Approach for a Fairer Future for Sport. Current Sports Medicine Reports, 2017, vol. 16, pp. 222-224. doi: 10.1249/JSR.0000000000000384.




DOI: https://doi.org/10.15826/analitika.2025.29.2.001

Ссылки

  • На текущий момент ссылки отсутствуют.